Back to List/Filter


TRANSFORM-2

NCT04468984

A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination With Ruxolitinib Versus Best Available Therapy in Subjects With Relapsed/Refractory Myelofibrosis (TRANSFORM-2)
Alfred Health (Haematology)
The Alfred, Commercial Road, Melbourne VIC, Australia
Recruiting
Primary Contact : John Nguyen, john.nguyen@alfred.org.au , 03 9076 7135
Calvary Mater Newcastle Hospital (Haematology)
Edith St & Platt St, Waratah NSW 2298, Australia
Recruiting
Primary Contact : Kath Hall, Kathy.Hall@calvarymater.org.au , 02 4014 4891
St Vincents Hospital Sydney (Haematology)
St Vincent's Hospital Sydney, Victoria Street, Darlinghurst NSW, Australia
Closed
Primary Contact : Georgia McCaughan, georgia.mccaughan@svha.org.au , 02 9355 5656

2020-000557-27M20-178

Interventional

Treatment - Drugs

Phase 3

18

100

04/12/2020

N/A

Open

By Specialist and/or Surgeon Referral

Any or not stated

No

No

No
Haematology
Myeloproliferative Disorders
Myelofibrosis
N/A

20120092